Genzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for Gaucher Disease

CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced positive new data from the Phase 3 ENGAGE and ENCORE studies of eliglustat tartrate, its investigational oral therapy for Gau... BiopharmaceuticalsGenzyme, Sanofi, eliglustat, Gaucher disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news